Partnerships

In August 2008, Valeant and GlaxoSmithKline (GSK) entered into an exclusive worldwide collaboration agreement for ezogabine/retigabine, a Phase III, first-in-class neuronal potassium channel opener for the adjunctive treatment of partial-onset seizures in adult patients with refractory epilepsy. Valeant and GSK filed a New Drug Application in the U.S. and a Marketing Authorization Application in Europe in 2009. The FDA action date is November 30, 2010.

Approved by the FDA in August 2008, Xenazine® is indicated for the treatment of chorea associated with Huntington's disease (HD). Xenazine® is marketed to U.S. specialist physicians through the sales force of Ovation Pharmaceuticals, Inc. (acquired by H. Lundbeck A/S in March 2009). Pursuant to a supply-and-distribution agreement, Biovail supplies Xenazine® tablets to Ovation for a variable percentage of the product's annual net sales, and pays a royalty to a third party that was acquired by H. Lundbeck A/S in July 2009.

Valeant is currently in discussion with potential partners for the out-licensing of taribarivin, a prodrug of ribavirin in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon.